315 related articles for article (PubMed ID: 28410420)
1. Comparison of cell-based assays for the identification and evaluation of competitive CXCR4 inhibitors.
Van Hout A; D'huys T; Oeyen M; Schols D; Van Loy T
PLoS One; 2017; 12(4):e0176057. PubMed ID: 28410420
[TBL] [Abstract][Full Text] [Related]
2. AMD3465, a monomacrocyclic CXCR4 antagonist and potent HIV entry inhibitor.
Hatse S; Princen K; De Clercq E; Rosenkilde MM; Schwartz TW; Hernandez-Abad PE; Skerlj RT; Bridger GJ; Schols D
Biochem Pharmacol; 2005 Sep; 70(5):752-61. PubMed ID: 16011832
[TBL] [Abstract][Full Text] [Related]
3. NeoR6 inhibits HIV-1-CXCR4 interaction without affecting CXCL12 chemotaxis activity.
Lapidot A; Peled A; Berchanski A; Pal B; Kollet O; Lapidot T; Borkow G
Biochim Biophys Acta; 2008 Jun; 1780(6):914-20. PubMed ID: 18410746
[TBL] [Abstract][Full Text] [Related]
4. A Flow Cytometry-based Assay to Identify Compounds That Disrupt Binding of Fluorescently-labeled CXC Chemokine Ligand 12 to CXC Chemokine Receptor 4.
Schoofs G; Van Hout A; D'huys T; Schols D; Van Loy T
J Vis Exp; 2018 Mar; (133):. PubMed ID: 29578516
[TBL] [Abstract][Full Text] [Related]
5. New AMD3100 derivatives for CXCR4 chemokine receptor targeted molecular imaging studies: synthesis, anti-HIV-1 evaluation and binding affinities.
Poty S; Désogère P; Goze C; Boschetti F; D'huys T; Schols D; Cawthorne C; Archibald SJ; Maëcke HR; Denat F
Dalton Trans; 2015 Mar; 44(11):5004-16. PubMed ID: 25640878
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the potential multiple binding modes of bicyclam, monocylam, and noncyclam small-molecule CXC chemokine receptor 4 inhibitors.
Wong RS; Bodart V; Metz M; Labrecque J; Bridger G; Fricker SP
Mol Pharmacol; 2008 Dec; 74(6):1485-95. PubMed ID: 18768385
[TBL] [Abstract][Full Text] [Related]
7. Fluorescent CXCL12AF647 as a novel probe for nonradioactive CXCL12/CXCR4 cellular interaction studies.
Hatse S; Princen K; Liekens S; Vermeire K; De Clercq E; Schols D
Cytometry A; 2004 Oct; 61(2):178-88. PubMed ID: 15382150
[TBL] [Abstract][Full Text] [Related]
8. Citrullination of CXCL12 differentially reduces CXCR4 and CXCR7 binding with loss of inflammatory and anti-HIV-1 activity via CXCR4.
Struyf S; Noppen S; Loos T; Mortier A; Gouwy M; Verbeke H; Huskens D; Luangsay S; Parmentier M; Geboes K; Schols D; Van Damme J; Proost P
J Immunol; 2009 Jan; 182(1):666-74. PubMed ID: 19109200
[TBL] [Abstract][Full Text] [Related]
9. Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells.
Burger M; Hartmann T; Krome M; Rawluk J; Tamamura H; Fujii N; Kipps TJ; Burger JA
Blood; 2005 Sep; 106(5):1824-30. PubMed ID: 15905192
[TBL] [Abstract][Full Text] [Related]
10. Dual-function CXCR4 antagonist polyplexes to deliver gene therapy and inhibit cancer cell invasion.
Li J; Zhu Y; Hazeldine ST; Li C; Oupický D
Angew Chem Int Ed Engl; 2012 Aug; 51(35):8740-3. PubMed ID: 22855422
[TBL] [Abstract][Full Text] [Related]
11. Pharmacology of AMD3465: a small molecule antagonist of the chemokine receptor CXCR4.
Bodart V; Anastassov V; Darkes MC; Idzan SR; Labrecque J; Lau G; Mosi RM; Neff KS; Nelson KL; Ruzek MC; Patel K; Santucci Z; Scarborough R; Wong RS; Bridger GJ; Macfarland RT; Fricker SP
Biochem Pharmacol; 2009 Oct; 78(8):993-1000. PubMed ID: 19540208
[TBL] [Abstract][Full Text] [Related]
12. Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4.
Hatse S; Princen K; Bridger G; De Clercq E; Schols D
FEBS Lett; 2002 Sep; 527(1-3):255-62. PubMed ID: 12220670
[TBL] [Abstract][Full Text] [Related]
13. CD4-Chemokine receptor hybrids in human immunodeficiency virus type 1 infection.
Klasse PJ; Rosenkilde MM; Signoret N; Pelchen-Matthews A; Schwartz TW; Marsh M
J Virol; 1999 Sep; 73(9):7453-66. PubMed ID: 10438835
[TBL] [Abstract][Full Text] [Related]
14. Small molecule CXCR4 chemokine receptor antagonists: developing drug candidates.
Khan A; Greenman J; Archibald SJ
Curr Med Chem; 2007; 14(21):2257-77. PubMed ID: 17896975
[TBL] [Abstract][Full Text] [Related]
15. CXCR4 inhibition with AMD3100 sensitizes prostate cancer to docetaxel chemotherapy.
Domanska UM; Timmer-Bosscha H; Nagengast WB; Oude Munnink TH; Kruizinga RC; Ananias HJ; Kliphuis NM; Huls G; De Vries EG; de Jong IJ; Walenkamp AM
Neoplasia; 2012 Aug; 14(8):709-18. PubMed ID: 22952424
[TBL] [Abstract][Full Text] [Related]
16. The CXCL12/CXCR4 axis as a therapeutic target in cancer and HIV-1 infection.
Patrussi L; Baldari CT
Curr Med Chem; 2011; 18(4):497-512. PubMed ID: 21143114
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of human immunodeficiency virus replication by a dual CCR5/CXCR4 antagonist.
Princen K; Hatse S; Vermeire K; Aquaro S; De Clercq E; Gerlach LO; Rosenkilde M; Schwartz TW; Skerlj R; Bridger G; Schols D
J Virol; 2004 Dec; 78(23):12996-3006. PubMed ID: 15542651
[TBL] [Abstract][Full Text] [Related]
18. The molecular pharmacology of AMD11070: an orally bioavailable CXCR4 HIV entry inhibitor.
Mosi RM; Anastassova V; Cox J; Darkes MC; Idzan SR; Labrecque J; Lau G; Nelson KL; Patel K; Santucci Z; Wong RS; Skerlj RT; Bridger GJ; Huskens D; Schols D; Fricker SP
Biochem Pharmacol; 2012 Feb; 83(4):472-9. PubMed ID: 22146583
[TBL] [Abstract][Full Text] [Related]
19. A low-molecular-weight inhibitor against the chemokine receptor CXCR4: a strong anti-HIV peptide T140.
Tamamura H; Xu Y; Hattori T; Zhang X; Arakaki R; Kanbara K; Omagari A; Otaka A; Ibuka T; Yamamoto N; Nakashima H; Fujii N
Biochem Biophys Res Commun; 1998 Dec; 253(3):877-82. PubMed ID: 9918823
[TBL] [Abstract][Full Text] [Related]
20. IL-24 inhibits lung cancer cell migration and invasion by disrupting the SDF-1/CXCR4 signaling axis.
Panneerselvam J; Jin J; Shanker M; Lauderdale J; Bates J; Wang Q; Zhao YD; Archibald SJ; Hubin TJ; Ramesh R
PLoS One; 2015; 10(3):e0122439. PubMed ID: 25775124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
